The COVID-19 pandemic has left a wake of victims with residual health issues, immunodeficiencies, and other health effects. With the official medical data changing everyday, the World Health Organization’s (WHO) newly officially recognized Long-COVID1 has now begun to acknowledge the long-term effects of the SARS-CoV-2 virus.
Moderna, who’s recent public focus has been mRNA prophylactic vaccines, has announced fourteen new mRNA vaccines, two specifically created to prevent transmission of HIV. While this will not cure the virus or resulting disease, Moderna states it will prevent infection from those who have not yet been infected, by producing an immunoresponse using genetically modified HIV envelope proteins injected routinely to prevent susceptibility to the virus.
While Moderna is a company whose primary goal is to generate profits for its investors by creating successful medical innovations, the company aims to market an HIV vaccine for people who do not have HIV. This may mark a significant leap in the evolution of finding a cure for HIV/AIDS however, how will Moderna plan to recoup the losses incurred from its development? Could America see a mandated HIV preventative mRNA vaccine incorporated into existing vaccine mandates? Could Moderna use this new mRNA HIV technology to combine two mRNAs (COVID-19 & HIV) in a single vial?
Moderna’s Announcement
Moderna has announced their new mRNA vaccine, eOD-GT8 60mer, to protect against HIV in those who do not have HIV. The vaccines will promote an immune response similar to the mRNA COVID-19 vaccines currently mandated in circulation.
On January 27th, 2022, International AIDS Vaccine Initiative, and Moderna—funded by the Bill and Melinda Gates Foundation—announced,
“”We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna’s mRNA platform. The search for an HIV vaccine has been long and challenging and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine,” [said] Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. “We are grateful to all of our partners and especially to the Bill & Melinda Gates Foundation for funding this trial.”
“We are very pleased to be partnering with IAVI and the Bill & Melinda Gates Foundation to apply our mRNA technology in the setting of HIV. At Moderna, we believe that mRNA offers a unique opportunity to address critical unmet public health needs around the world,” said Stephen Hoge, M.D., President of Moderna. “We believe advancing this HIV vaccine program in partnership with IAVI and Scripps Research is an important step in our mission to deliver on the potential for mRNA to improve human health.”
The new concoction, deemed “mRNA-1644”, is stated to be a prophylactic on the company’s website2. This means it can be used to prevent HIV in those who do not currently have HIV, by inserting a genetically modified form of the HIV envelope protein. Despite that the injection uses the same mRNA genome technology as Moderna’s current coronavirus concoctions, will it be as successful as their current mRNA medical breakthrough vaccine?
mRNA-1644
On April 14th, 2021, Moderna gave an announcement to their investors including updates on their current mRNA HIV vaccine technology3.
“mRNA-1644 is a novel approach to HIV vaccine strategy in humans designed to elicit broadly neutralizing HIV-1 antibodies (bNAbs) and is being developed in collaboration with the International AIDS Vaccine Initiative (IAVI) and the Bill and Melinda Gates Foundation (BMGF). A Phase 1 study for mRNA-1644 will use iterative human testing to validate the approach and antigens and multiple novel antigens will be used for germline-targeting and immuno-focusing.”
“A second approach, mRNA-1574, is being evaluated in collaboration with the National Institutes of Health (NIH) and includes multiple native-like trimer antigens. The Company expects to begin phase 1 clinical trials for both mRNA-1644 and mRNA-1574 in 2021.”
“Dr. William Schief is presenting new data from the Phase 1 study of the IAVI G001 HIV vaccine candidate, which established the proof-of-principle for germline-targeting vaccine design in humans.”
“This Phase 1 study confirms that vaccines can induce broadly neutralizing antibodies, a necessary strategy to develop an HIV vaccine.”
“The development is expected to require multiple iterative human clinical trials. Moderna’s mRNA technology may have promise in HIV vaccine development. Three Phase 1 trials studying HIV vaccine concepts delivered by Moderna mRNA are expected to launch in 2021. The speed and cost advantages of Moderna’s mRNA vaccine technology have enabled Moderna’s collaborators to develop these trials rapidly.”
Experimental Trials
Beginning on November 12th, 2021, Moderna recruited fifty-six healthy individuals between 18 – 51 years of age, who were not infected with HIV for their experimental mRNA trials4. The human trials are expected to last until April 11th, 2023. The primary purpose of these trials, is “prevention,” meaning the hosts of the in vivo experiment will themselves not be infected with HIV.
The volunteers will randomly be injected with either both eOD-GT8 60mer, and Core-g28v2 60mer mRNA, or just one of the newly-formed mRNA concoctions.
- eOD-GT8 60mer mRNA – “An engineered HIV envelope protein expressed as a nanoparticle and designed to target germline responses to lead to neutralizing antibody development.”
- Core-g28v2 60mer mRNA – [An] “Engineered HIV envelope protein delivered through messenger RNA and designed to target germline B cells and guide their maturation toward the development of neutralizing antibody responses.”
Inclusion criteria included healthy adults age 18-51, those willing to undergo HIV testing, receive HIV test results, and give “donations of blood, or any other tissues during the study and, for those who test HIV-positive due to IP-induced antibodies, until the anti-HIV antibody titers become undetectable.”
Exclusion criteria included anyone who tested positive for HIV-1 or HIV-2, reported behavior that put the participant at risk for HIV infection within 6 months prior to screening, three or more sexual partners, bleeding disorders, history of seizures, history of suicide, history of substance abuse, history of alcohol abuse, engaged in another HIV vaccine clinical study, tested postive in the past four months for syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus-2, chlamydia, pelvic inflammatory disease, trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B-or hepatitis C; and the applicant must weigh over one-hundred pounds.
Statements
“We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna’s mRNA platform. The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine,” proclaimed Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. “We are grateful to all of our partners and especially to the Bill & Melinda Gates Foundation for funding this trial.”
“We are very pleased to be partnering with IAVI and the Bill & Melinda Gates Foundation to apply our mRNA technology in the setting of HIV. At Moderna, we believe that mRNA offers a unique opportunity to address critical unmet public health needs around the world,” said Stephen Hoge, M.D., President of Moderna. “We believe advancing this HIV vaccine program in partnership with IAVI and Scripps Research is an important step in our mission to deliver on the potential for mRNA to improve human health.”
Conclusion
While this is a start of finding hope for a conclusive treatment for HIV/AIDS, mRNA-1644 is not a treatment for people who currently have HIV. It is a preventative immune system stimulation mRNA therapy which works only for those who are not currently infected with HIV. The clinical trials involved patients who did not have HIV, and the formula is stated to be used as a preventative treatment. For the development of a cure for AIDS/HIV many individuals infected with HIV may also have the symptoms excluded from clinical trials—in these cases, how will this vaccine data apply?
This technology is the first step to one day allow the solution to HIV/AIDS relies on the rapid expansion of mRNA technology, and deployment of Moderna’s mRNA injectables. Beyond the hope for a cure, Moderna’s announcement reveals the company’s confidence that the pharmaceutical manufacturers, their funders, and shareholders, will continue to accumulate mass revenue through the development of mRNA inoculations.
mRNA Propaganda. If Dr. Fauci told Americans that taking the HIV mRNA vaccine could eradicate HIV/AIDS off the face of the Earth for future generations, some individuals would demand these, too, be mandated vaccinations. This revolutionary HIV technology, does not have a proven effect on those with existing HIV, however it could provide evidence that would indicate the ability to prevent HIV transmission in those without the virus. The development of a working mRNA against HIV could provide enough evidence to be the next mandated inoculation given to children at birth.
As the science—and carefully coordinated clinical trial data—shows a stronger efficacy over the use traditional vitamins, exercise, and medicine, mRNA technology could be the next state mandated essential biological upgrades of the future. The iatrarchy views the use of mass mRNA as a method to provide a more stable medically controlled environment, with less chance for virus and disease, not only reducing hospitalizations, but also bringing more revenue to pharmaceutical manufacturers and their affiliates in ways previously unimaginable. What are the costs to the longevity of our species? Despite our biological generational hazards to long-term cell manipulation, will mRNA become a necessary component of the human immune system?
JMBK.NEWS 